{"id":1063735,"date":"2012-06-01T20:10:40","date_gmt":"2012-06-01T20:10:40","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/antioxidant-shows-promise-as-treatment-for-certain-features-of-autism-study-finds\/"},"modified":"2024-08-17T20:32:15","modified_gmt":"2024-08-18T00:32:15","slug":"antioxidant-shows-promise-as-treatment-for-certain-features-of-autism-study-finds","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/autism\/antioxidant-shows-promise-as-treatment-for-certain-features-of-autism-study-finds.php","title":{"rendered":"Antioxidant shows promise as treatment for certain features of autism, study finds"},"content":{"rendered":"<p><p>    TORONTO , June 1, 2012 \/CNW\/ - A specific antioxidant    supplement may be an effective therapy for some features of    autism, according to a pilot trial from the Stanford University    School of Medicine and Lucile Packard Children's Hospital that    involved 31 children with the disorder.  <\/p>\n<p>    The antioxidant, called PharmaNAC, contains    pharmaceutical-grade N-acetylcysteine and is specially-packed    to preserve its potency. PharmaNAC lowered irritability in    children with    autism as well as reduced the children's repetitive    behaviors. The researchers emphasized that the findings must be    confirmed in a larger trial.  <\/p>\n<p>    Irritability affects 60 to 70 percent of children with autism.    \"We're not talking about mild things: This is throwing,    kicking, and hitting; the child needing to be restrained,\" said    Antonio    Hardan , MD, the primary author of the new study. \"It    can affect learning, vocational activities and the child's    ability to participate in autism therapies.\"  <\/p>\n<p>    The study appears in the June 1 issue of Biological    Psychiatry. Hardan is an associate professor of psychiatry    and behavioral sciences at Stanford and director of the Autism    and Developmental Disabilities Clinic at Packard Children's.  <\/p>\n<p>    Finding new medications to treat autism and its symptoms is a    high priority for researchers. Currently, irritability, mood    swings and aggression, all of which are considered associated    features of autism, are treated with second-generation    antipsychotics. But these drugs cause significant side effects,    including weight gain, involuntary motor movements and    metabolic syndrome, which increases diabetes risk. By contrast,    side effects of PharmaNAC are generally occasional and mild,    with gastrointestinal problems such as constipation, nausea,    diarrhea and decreased appetite. Most people report no side    effects. It is easy for children to take because the PharmaNAC    tablet is dropped into a small glass of water to make a fizzy    drink, so the child can take it without having to swallow a    pill or capsule.  <\/p>\n<p>    The state of drug treatments for autism's core features, such    as social deficits, language impairment and repetitive    behaviors, is also a major problem. \"Today, in 2012, we have no    effective medication to treat repetitive behavior such as hand    flapping or any other core features of autism,\" Hardan said.    PharmaNAC could be the first medication available to treat    repetitive behavior in autism  if the findings hold up when    scrutinized further.  <\/p>\n<p>    The study tested children with autism ages three to 12. They    were physically healthy and were not planning any changes in    their established autism treatments during the trial. In the    double-blind study design, children received PharmaNAC or a    placebo of identical appearance and taste for 12 weeks. The    product used was the effervescent, pharmaceutical-grade    preparation donated by BioAdvantex Pharma Inc., the    manufacturer.  <\/p>\n<p>    Subjects were evaluated before the trial began and every four    weeks during the study using several standardized surveys that    measure problem behaviors, social behaviors, autistic    preoccupations and drug side effects.  <\/p>\n<p>    During the 12-week trial, PharmaNAC treatment decreased    irritability scores from 13.1 to 7.2 on the Aberrant Behavior    Checklist, a widely used clinical scale for assessing    irritability. The change is not as large as that seen in    children taking antipsychotics. \"But this is still a    potentially valuable tool to have before jumping on these big    guns,\" Hardan said.  <\/p>\n<p>    In addition, according to two standardized measures of autism    mannerisms and stereotypic behavior, children taking PharmaNAC    showed a decrease in repetitive and stereotyped behaviors.  <\/p>\n<\/p>\n<p>Read the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/antioxidant-shows-promise-treatment-certain-120000986.html;_ylt=A2KJjb2tIclPUQQAbzj_wgt.\" title=\"Antioxidant shows promise as treatment for certain features of autism, study finds\" rel=\"noopener\">Antioxidant shows promise as treatment for certain features of autism, study finds<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> TORONTO , June 1, 2012 \/CNW\/ - A specific antioxidant supplement may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that involved 31 children with the disorder. The antioxidant, called PharmaNAC, contains pharmaceutical-grade N-acetylcysteine and is specially-packed to preserve its potency. PharmaNAC lowered irritability in children with autism as well as reduced the children's repetitive behaviors.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/autism\/antioxidant-shows-promise-as-treatment-for-certain-features-of-autism-study-finds.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246879],"tags":[],"class_list":["post-1063735","post","type-post","status-publish","format-standard","hentry","category-autism"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063735"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063735"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}